"
data-check-event-based-preview=""
data-is-vertical-video-embed="false"
data-network-id=""
data-publish-date="2023-10-21T12:27:21Z"
data-video-section="health"
data-canonical-url="https://www.cnn.com/videos/health/2023/10/19/ultraprocessed-food-nutrition-lbb-contd-orig-no.cnn"
data-branding-key="life-but-better-diet"
data-video-slug="ultraprocessed food nutrition lbb contd orig no"
data-first-publish-slug="ultraprocessed food nutrition lbb contd orig no"
data-video-tags="business and industry sectors,business, economy and trade,diet and nutrition,diet, nutrition and fitness,dietitians and nutritionists,domestic alerts,domestic-health and science,food and beverage industry,food and drink,food production industry,health and medical,health care,health care professionals,iab-business and finance,iab-food & drink,iab-food industry,iab-grocery shopping,iab-healthcare industry,iab-healthy cooking and eating,iab-healthy living,iab-industries,iab-medical health,iab-nutrition,iab-retail industry,iab-shopping,international alerts,international-health and science,nutrition,retail and wholesale trade,supermarkets and groceries"
data-details="">
Video Ad Feedback
What is ultraprocessed food? Nutritionist explains why it can taste different
"
data-check-event-based-preview=""
data-is-vertical-video-embed="false"
data-network-id=""
data-publish-date="2024-03-04T20:15:54Z"
data-video-section="health"
data-canonical-url="https://www.cnn.com/videos/health/2024/03/04/otc-birth-control-pill-perrigo-howard-cnc-vpx.cnn"
data-branding-key=""
data-video-slug="otc birth control pill perrigo howard cnc vpx"
data-first-publish-slug="otc birth control pill perrigo howard cnc vpx"
data-video-tags="brand safety-nsf health issues,brand safety-nsf mature,brand safety-nsf sensitive,companies,continents and regions,contraception,domestic alerts,domestic-health and science,health and medical,iab-birth control,iab-diseases and conditions,iab-medical health,iab-reproductive health,iab-sexual health,international alerts,international-health and science,north america,perrigo,sexual and reproductive health,the americas,united states"
data-details="">
Video Ad Feedback
Here's where to find the first approved over-the-counter oral contraceptive
"
data-check-event-based-preview=""
data-is-vertical-video-embed="false"
data-network-id=""
data-publish-date="2024-02-02T12:31:47Z"
data-video-section="health"
data-canonical-url="https://www.cnn.com/videos/health/2024/01/29/grocery-stores-ultraprocessed-foods-lbb-contd-orig-no.cnn"
data-branding-key="life-but-better-diet"
data-video-slug="grocery stores ultraprocessed foods lbb contd orig no"
data-first-publish-slug="grocery stores ultraprocessed foods lbb contd orig no"
data-video-tags="business and industry sectors,business, economy and trade,canned food,company activities and management,consumer products,diet and nutrition,diet, nutrition and fitness,dietitians and nutritionists,domestic alerts,domestic-business,domestic-health and science,food and beverage industry,food and drink,food packaging,food production industry,food products,health and medical,health care,health care professionals,iab-business,iab-business and finance,iab-business operations,iab-food & drink,iab-food industry,iab-healthcare industry,iab-healthy cooking and eating,iab-healthy living,iab-industries,iab-medical health,iab-nutrition,international alerts,international-business,international-health and science,kinds of foods and beverages,nutrition,product management,product packaging"
data-details="">
Video Ad Feedback
Watch a nutritionist explain the food labels behind three everyday foods
Two people who received Pfizer’s respiratory syncytial virus (RSV) vaccine during a clinical trial were later diagnosed with Guillain-Barre syndrome, and the US Food and Drug Administration has asked Pfizer to conduct a safety study if the shot is approved, according to agency documents released Friday.
The cases were confirmed in two adults in their 60s who were among 20,000 vaccine recipients in Pfizer’s Phase 3 clinical trial. One person’s illness had completely resolved after three months, and another was improving after six months. There were no Guillain-Barre cases among people who didn’t receive the shot.
“Given the temporal association and biological plausibility, FDA agrees with the assessments of the investigators that these events were possibly related to study vaccine. … Therefore, [Guillain-Barre] is being considered an important potential risk,” the FDA says in the documents, which were released ahead of a meeting of its independent vaccine advisers, the Vaccines and Related Biological Products Advisory Committee, on Tuesday and Wednesday.
The committee is scheduled to discuss and make recommendations on RSV vaccines for adults 60 and older from Pfizer and GSK.
Guillain-Barre syndrome is a rare neurological disorder in which the immune system attacks its own nerves, causing muscle weakness and sometimes paralysis. Although most people recover completely, some cases can be fatal or have lasting effects.
"
data-timestamp-html=""
data-check-event-based-preview=""
data-is-vertical-video-embed="false"
data-network-id=""
data-publish-date="2016-02-29T21:48:33Z"
data-video-section="health"
data-canonical-url="https://www.cnn.com/videos/health/2016/02/29/guillain-barre-syndrome-explainer-nccorig.cnn"
data-branding-key=""
data-video-slug="guillain-barre-syndrome-explainer-nccorig"
data-first-publish-slug="guillain-barre-syndrome-explainer-nccorig"
data-video-tags="autoimmune disorders,brand safety-nsf health issues,brand safety-nsf sensitive,diseases and disorders,domestic alerts,domestic-health and science,elizabeth cohen,health and medical,iab-brain and nervous system disorders,iab-diseases and conditions,iab-medical health,immune system disorders,international alerts,international-health and science,misc people,neurological disorders and injuries"
data-details="">
The incidence of Guillain-Barre is about 1.5 to 3 cases for 100,000 adults over age 60 in the US annually, according to the FDA.
“Given the higher than background rate of GBS observed in the Phase 3 study, FDA will recommend a postmarketing study and enhanced surveillance for further evaluation of GBS and other immune-mediated demyelinating conditions with postmarketing use,” the FDA says.
In a briefing document submitted for next week’s meetings, Pfizer says that the cases have other possible explanations and that its shot is a “well-tolerated and safe vaccine, with a benefit-to-risk ratio that is favorable.” The company says it will conduct a safety study on Guillain-Barre syndrome if its RSV shot is approved.
RSV is a highly contagious virus that causes flu-like illness in people of all ages that increases in severity with age. According to the US Centers for Disease Control and Prevention, RSV is responsible for an estimated 177,000 hospitalizations and 14,000 deaths per year among adults 65 or older.
There are no vaccines approved for immunization against RSV in either children or with adults.
The Pfizer vaccine was 66.7% effective at preventing moderated lower respiratory tract illness with two or more symptoms and 85.7% effective at preventing severe illness, the FDA documents say.
GSK’s RSV vaccine candidate for older adults was 94.1% effective at preventing severe lower respiratory tract disease and 82.6% effective in preventing illness overall. The company similarly reported a potential case of Guillain-Barre syndrome among vaccine recipients but said there was insufficient evidence to confirm a diagnosis. The FDA considers the case to be related to the vaccine and said it will review GSK’s safety plan.
Data from both vaccines was discussed Thursday during a meeting of the CDC’s Advisory Committee on Immunization Practices. The working group concluded that the vaccines “demonstrated significant efficacy against lower respiratory tract illness caused by RSV among older adults” but that “post licensure surveillance for both safety and vaccine effectiveness will be critical” if the vaccines are approved by the FDA.
Correction: A previous version of this story incorrectly described the efficacy of GSK’s RSV vaccine candidate against severe disease.